VT News
Brent Thompson

Brent Thompson

Ask VT AI
View News Summary
  • Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
  • FDA moves to ban ingestible fluoride for children, citing concerns over potential health risks, sparking debate among parents and professionals.
  • Sony posts record profit but warns of tariff impact, as it undergoes strategic changes under new CEO.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Latest News
Ask VT AI
View News Summary
  • Exelixis and Ensysce report strong biotech advances, with Exelixis' cancer drug Cabometyx driving revenue growth and Ensysce's opioid-use-disorder drug PF9001 showing promise.
  • FDA moves to ban ingestible fluoride for children, citing concerns over potential health risks, sparking debate among parents and professionals.
  • Sony posts record profit but warns of tariff impact, as it undergoes strategic changes under new CEO.
20 hours
USA flag

United States Politics

Discover the latest news, candidates, 
and key topics of US politics

Most Reported By
News from Brent Thompson

Top Topics

Trending in U.S.

World

Sport